Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087282 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00087282: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00087282 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087282, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with flavopiridol works in treating patients with advanced liver cancer.
Interventions
- DRUG irinotecan hydrochloride
- DRUG alvocidib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-06 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
What the finished NCT00087282 record still lists
NCT00087282 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00087282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00087282 about?
NCT00087282 is a clinical study titled "Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer". RATIONALE: Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with...
What is the current status of trial NCT00087282?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-06. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00087282?
The interventions under investigation include: irinotecan hydrochloride (DRUG), alvocidib (DRUG).
Who is sponsoring clinical trial NCT00087282?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia